A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug plan costs but promising pharmaceutical innovation, says Joe Farago, executive director of private payers and investment at Innovative Medicines Canada.
The Patented Medicine Prices Review Board (PMPRB) ensures patented medicines sold in Canada are not excessively priced. IMC has highlighted how changes to the PMPRB affect patient access to medicines and Canada’s attractiveness for future pharmaceutical innovation.
Ottawa, June 6, 2023 – Recently released Statistics Canada data demonstrates the economic impact of the innovative research and development […]
Ottawa, ON – Innovative Medicines Canada (IMC) welcomes the new leadership of the Patented Medicine Prices Review Board (PMPRB) with […]
The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.